This page provides a comparative analysis of nitric oxide (NO) signaling dysregulation across 4R-tauopathies, a group of neurodegenerative disorders characterized by accumulation of 4-repeat tau isoforms. These include Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), [Astrocytic Gliosis (AGD) (primary 4R-tauopathy, not yet represented in NeuroWiki)], [Guam Parkinsonism-Dementia Complex (GGT)], and FTDP-17 (MAPT mutations).
While the general Nitric Oxide Signaling in Neurodegeneration page covers broad mechanisms, this page focuses on disease-specific alterations in NO signaling that are particularly relevant to 4R-tau pathology.
All 4R-tauopathies share key pathological features that intersect with NO signaling pathways:
nNOS is constitutively expressed in discrete neuronal populations and produces brief, localized NO pulses in response to calcium/calmodulin activation. In 4R-tauopathies:
| Disease | nNOS Alteration | Evidence |
|---|---|---|
| PSP | Increased nNOS in brainstem nuclei | [1] |
| CBD | nNOS dysregulation in basal ganglia | [2] |
| FTDP-17 | nNOS linked to excitotoxic mechanisms | [3] |
nNOS plays a dual role:
eNOS primarily regulates cerebral blood flow and blood-brain barrier (BBB) integrity:
| Disease | eNOS Alteration | Evidence |
|---|---|---|
| PSP | Reduced eNOS, vascular dysfunction | [4] |
| CBD | BBB compromise in affected regions | [5] |
| GGT | Vascular involvement documented | [4:1] |
eNOS dysfunction contributes to:
iNOS produces high-output, sustained NO when induced by cytokines. This is a major driver of chronic neuroinflammation:
| Disease | iNOS Expression | Evidence |
|---|---|---|
| PSP | Strong iNOS in microglia, astrocytes | [6] |
| CBD | iNOS in activated glia | [7] |
| AGD | iNOS in astrocytes | [5:1] |
| GGT | iNOS in affected brain regions | [4:2] |
NO plays a critical role in synaptic plasticity, and dysregulation contributes to cognitive decline in 4R-tauopathies:
When NO superabounds with reactive oxygen species (ROS), peroxynitrite (ONOO⁻) forms - a highly reactive species that causes widespread damage:
| Mechanism | Effect on Tau | Disease Relevance |
|---|---|---|
| Tau nitration | Tyrosine nitration accelerates aggregation | All 4R-tauopathies |
| Tau hyperphosphorylation | Nitration at Y29, Y18 promotes kinase activation | PSP, CBD |
| Tau cleavage | Peroxynitrite enhances caspase cleavage | FTDP-17 |
| Oligomerization | Nitrated tau forms toxic oligomers | All 4R-tauopathies |
Research demonstrates that peroxynitrite mediates tau hyperphosphorylation through activation of multiple kinases including GSK-3β and CDK5 [8].
S-nitrosylation is the covalent addition of NO to cysteine residues, altering protein function. This is increasingly recognized in tauopathies [9]:
| Protein | S-Nitrosylation Effect | Disease |
|---|---|---|
| Tau | Promotes aggregation | All tauopathies |
| Caspase-3 | Activates apoptosis | PSP, CBD |
| Dynamin-1 | Impairs synaptic vesicle recycling | CBD |
| Parkin | Dysregulates mitophagy | PSP |
| XBP1 | Triggers ER stress | FTDP-17 |
In PSP, S-nitrosylation contributes to:
PSP shows particularly prominent NO dysregulation:
Key papers:
CBD shows distinct NO signaling patterns:
Therapeutic implications:
FTDP-17 provides insight into tau-NO interactions:
Key mechanisms:
GGT represents an environmental 4R-tauopathy:
| Strategy | Target | Status |
|---|---|---|
| NOS inhibitors | nNOS/iNOS | Preclinical |
| Peroxynitrite scavengers | ONOO⁻ | Preclinical |
| nNOS-selective | AR-R17477 | Research |
| iNOS-selective | 1400W | Research |
| sGC stimulators | cGMP pathway | Investigational |
| Feature | PSP | CBD | AGD | GGT | FTDP-17 |
|---|---|---|---|---|---|
| nNOS | ↑ | ↑ | ↑ | ↑ | ↑ |
| eNOS | ↓ | ↓ | ↓ | ↓ | ↓ |
| iNOS | ↑↑ | ↑ | ↑↑ | ↑ | ↑ |
| Peroxynitrite | ↑↑ | ↑ | ↑↑ | ↑ | ↑↑ |
| Tau nitration | Yes | Yes | Yes | Yes | Yes |
| S-nitrosylation | Yes | Yes | Yes | No | Yes |
Riddell NA, et al. Neuronal nitric oxide synthase and tau pathology. 2008. ↩︎
Chung KK, et al. The role of nitric oxide in tauopathy. 2013. ↩︎
Guix FX, et al. The physiology and pathophysiology of nitric oxide in the brain. 2005. ↩︎
Stein L, et al. Nitric oxide in neurodegenerative disorders. 2012. ↩︎ ↩︎ ↩︎
Szabó C, et al. Nitric oxide and peroxynitrite in health and disease. 2016. ↩︎ ↩︎
Suzuki M, et al. iNOS expression in progressive supranuclear palsy. 2015. ↩︎ ↩︎
Terada K, et al. Role of inducible nitric oxide synthase in corticobasal degeneration. 2018. ↩︎
Sadai Y, et al. Peroxynitrite mediates tau hyperphosphorylation. 2006. ↩︎
Wang J, et al. S-nitrosylation in tauopathies. 2014. ↩︎